Literature DB >> 16166078

Interaction between the androgen receptor and RNase L mediates a cross-talk between the interferon and androgen signaling pathways.

David J Bettoun1, Angela Scafonas, Su Jane Rutledge, Paul Hodor, Oliver Chen, Carlo Gambone, Robert Vogel, Sheila McElwee-Witmer, Chang Bai, Leonard Freedman, Azriel Schmidt.   

Abstract

Signaling by androgens and interferons (IFN) plays an important role in prostate cancer initiation and progression. Using microarray analysis, we describe here a functional cross-talk between dihydrotestosterone and interferon signaling. Glutathione S-transferase pull-down and co-immunoprecipitation experiments reveal that the androgen receptor and the interferon-activated RNase L interact with each other in a ligand-dependent manner. Furthermore, overexpression of wild type RNase L confers IFN sensitivity to a dihydrotestosterone-inducible reporter gene, whereas R462Q-mutated RNase L does not. Based on our data we hypothesize that in 22RV1 cells, activated androgen receptor (AR) contributes to the insensitivity to IFN of the cell. Accordingly, we show that AR knockdown restores responsiveness to IFNgamma. Our findings support a model in which both the activation of AR and the down-regulation of IFN signaling can synergize to promote cell survival and suppress apoptosis. This model provides the molecular basis to understand how mutated RNase L can lead to early onset PCa and illustrates how inflammatory cytokines and nuclear hormone signaling contribute to tumor development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166078     DOI: 10.1074/jbc.C500324200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology.

Authors:  Azriel Schmidt; Donald B Kimmel; Chang Bai; Angela Scafonas; Sujane Rutledge; Robert L Vogel; Sheila McElwee-Witmer; Fang Chen; Pascale V Nantermet; Viera Kasparcova; Chih-Tai Leu; Hai-Zhuan Zhang; Mark E Duggan; Michael A Gentile; Paul Hodor; Brenda Pennypacker; Patricia Masarachia; Evan E Opas; Sharon A Adamski; Tara E Cusick; Jiabing Wang; Helen J Mitchell; Yuntae Kim; Thomayant Prueksaritanont; James J Perkins; Robert S Meissner; George D Hartman; Leonard P Freedman; Shun-ichi Harada; William J Ray
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

2.  Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.

Authors:  Nanmeng Yu; Shelby Puckett; Peter A Antinozzi; Scott D Cramer; Douglas S Lyles
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

3.  Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families.

Authors:  Danielle M Karyadi; Shanshan Zhao; Qianchuan He; Laura McIntosh; Jonathan L Wright; Elaine A Ostrander; Ziding Feng; Janet L Stanford
Journal:  Int J Cancer       Date:  2014-10-13       Impact factor: 7.396

4.  Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival.

Authors:  Athina Kladi-Skandali; Konstantinos Mavridis; Andreas Scorilas; Diamantis C Sideris
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-27       Impact factor: 4.553

5.  Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.

Authors:  Shanora G Brown; Ashley E Knowell; Aisha Hunt; Divya Patel; Sushma Bhosle; Jaideep Chaudhary
Journal:  Prostate       Date:  2014-10-18       Impact factor: 4.104

6.  Joint effects of inflammation and androgen metabolism on prostate cancer severity.

Authors:  Timothy R Rebbeck; Hanna Rennert; Amy H Walker; Saarene Panossian; Teo Tran; Kyle Walker; Elaine Spangler; Margerie Patacsil-Coomes; Rajeev Sachdeva; Alan J Wein; S Bruce Malkowicz; Charnita Zeigler-Johnson
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

7.  Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands.

Authors:  Azriel Schmidt; Shun-Ichi Harada; Donald B Kimmel; Chang Bai; Fang Chen; Su Jane Rutledge; Robert L Vogel; Angela Scafonas; Michael A Gentile; Pascale V Nantermet; Sheila McElwee-Witmer; Brenda Pennypacker; Patricia Masarachia; Soumya P Sahoo; Yuntae Kim; Robert S Meissner; George D Hartman; Mark E Duggan; Gideon A Rodan; Dwight A Towler; William J Ray
Journal:  J Biol Chem       Date:  2009-10-21       Impact factor: 5.157

Review 8.  Pathologic effects of RNase-L dysregulation in immunity and proliferative control.

Authors:  Heather J Ezelle; Bret A Hassel
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

9.  RNase L interacts with Filamin A to regulate actin dynamics and barrier function for viral entry.

Authors:  Krishnamurthy Malathi; Mohammad Adnan Siddiqui; Shubham Dayal; Merna Naji; Heather J Ezelle; Chun Zeng; Aimin Zhou; Bret A Hassel
Journal:  mBio       Date:  2014-10-28       Impact factor: 7.867

10.  RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells.

Authors:  Shubham Dayal; Jun Zhou; Praveen Manivannan; Mohammad Adnan Siddiqui; Omaima Farid Ahmad; Matthew Clark; Sahezeel Awadia; Rafael Garcia-Mata; Lirim Shemshedini; Krishnamurthy Malathi
Journal:  Int J Mol Sci       Date:  2017-03-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.